Quarterly report pursuant to Section 13 or 15(d)

CONDENDSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

v3.21.1
CONDENDSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Subordinate Voting Shares
Super Voting Shares
Share Capital
Accumulated Deficit
Total
Beginning balance, shares at Dec. 31, 2019 32,844 203      
Beginning balance at Dec. 31, 2019     $ 96,160 $ (72,474) $ 23,686
Net loss (7,874) (7,874)
Share-based compensation expense, shares 144        
Share-based compensation expense     1,612   1,612
Ending balance, shares at Mar. 31, 2020 32,988 203      
Ending balance at Mar. 31, 2020     97,772 (80,348) 17,424
Beginning balance, shares at Dec. 31, 2020 57,617 203      
Beginning balance at Dec. 31, 2020     125,540 (94,384) 31,156
Net loss (6,719) (6,719)
Shares issued in connection with conversion of convertible debentures, shares 1,390      
Shares issued in connection with conversion of convertible debentures     277   277
Issuance of shares associated with acquisitions, shares 22,644      
Issuance of shares associated with acquisitions     34,237   34,237
Exercise of warrants, shares 1,324      
Exercise of warrants     665   665
Share-based compensation expense, shares 246      
Share-based compensation expense     287   287
Ending balance, shares at Mar. 31, 2021 83,221 203      
Ending balance at Mar. 31, 2021     $ 161,006 $ (101,103) $ 59,903